As per the sources, A biotechnology startup company in southwestern Japan will start human clinical trials for a drug to treat COVID-19 in coming year 2021.
Bonac Corp, based in Kurume, Fukuoka Prefecture, said it has developed 72 candidates for nucleic acid medicines and tested their effectiveness against the respiratory disease caused by the novel COVID, in joint research with the Fukuoka Institute of Health and Environmental Sciences since June.
Read Also – Fujitsu to conduct trail of AI-based technologies to optimize disaster evacuation center management
According to the recent press by this startup, Ten of the candidates had proven to be effective in “significantly reducing the replication” of the virus, demonstrating the effectiveness of these medicines for COVID-19.
The research team for the betterment in trail and experiment has reduced the number of candidates from 10 to three that are highly stable in the human body and can be effective even in small quantities.
After selecting one of them through non-clinical tests, clinical trials involving human subjects will be launched next year.
Bonac said in later conversation, The prospective drug could also be developed for treatment of Middle East respiratory syndrome, or MERS, and severe acute respiratory syndrome, or SARS, both of which are similar to COVID-19 and still have no treatments.
If we talk about the startup,it was established in 2010,has said that by using its “RNA interference technology,” it will attempt to create a drug that can decompose the genomic RNA of the coronavirus and induce antiviral effects in infected patients.
In Biological terms, DNA and RNA, which are collectively called nucleic acids, can be found in the cells of all living organisms. Their tasks are to store and transmit genetic information.